Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM: Antidepressants for TRD in older adults
NCT02960763Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2017
- Primary completion
- Sep 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 4, randomised, single-blind trial of aripiprazole, bupropion, lithium and nortriptyline in treatment-resistant depression (TRD) (5 arms), sponsored by Washington University School of Medicine. Primary endpoints: Psychological Well-Being at 20 weeks, Remission from Depression at 20 weeks and 1 more. Started Feb 2017; status: completed.
02
Drugs
aripiprazolebupropionlithiumnortriptyline
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02960763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960763.